SPIA
BLRX

Steward Partners Investment Advisory’s BioLineRX BLRX Stock Holding History

Steward Partners Investment Advisory’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25
Closed -$1K – 3234
2022
Q2 		$1K Hold
25
– – ﹤0.01% 3086
2022
Q1 		$2K Hold
25
– – ﹤0.01% 3067
2021
Q4 		$2K Hold
25
– – ﹤0.01% 3004
2021
Q3 		$3K Hold
25
– – ﹤0.01% 2911
2021
Q2 		$3K Sell
25
-5
-17% -$588 ﹤0.01% 6763
2021
Q1 		$3.35K Buy
30
+2
+7% +$240 ﹤0.01% 3106
2020
Q4 		$3K Buy
+28
New +$2.45K ﹤0.01% 2615

Other funds holding BLRX

ACM
Altium Capital Management New York $42M AUM
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Steward Partners Investment Advisory's BLRX Position: Q3 2022 in Review

Steward Partners Investment Advisory sold out of BioLineRX (BLRX) in Q3 2022, closing a stake of 25 shares — an estimated $1K sold.

Steward Partners Investment Advisory first reported a position in BLRX in Q4 2020 and held it in 7 quarters. The position peaked at $3.35K in Q1 2021. 28 funds tracked by Wall St. Rank hold BLRX as of Q3 2022.

  • Steward Partners Investment Advisory reported no remaining BioLineRX position as of Q3 2022 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 25 BioLineRX shares in Q3 2022, an estimated $1K.
  • Steward Partners Investment Advisory first reported a position in BioLineRX in Q4 2020 and held it in 7 quarters.
  • Steward Partners Investment Advisory's BioLineRX position peaked at $3.35K in Q1 2021.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q3 2022.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2022, filed 10 Nov 2022.